Works matching IS 1120-009X AND VI 36 AND IP 8 AND DT 2024

Results: 9

Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with Staphylococcus Aureus by pharmacokinetic/pharmacodynamic analysis.

Published in:

Journal of Chemotherapy (Taylor & Francis Ltd), 2024, v. 36, n. 8, p. 709, doi. 10.1080/1120009X.2024.2343963

By:

Xu, Gaoqi;
Liu, Xin;
Wang, Jiaqi;
Mei, Yuqing;
Yang, Dihong;
He, Chaoneng;
Zhong, Like;
Zhu, Junfeng;
Ding, Haiying;
Fang, Luo

Publication type:

Article

Efficacy and safety of generic cefoperazone/sulbactam versus branded cefoperazone/sulbactam in the treatment of bacterial infections: a systematic review and meta-analysis.

Published in:

Journal of Chemotherapy (Taylor & Francis Ltd), 2024, v. 36, n. 8, p. 698, doi. 10.1080/1120009X.2024.2343961

By:

Wu, Rui;
Wang, Xuechang;
Cui, Pumei;
Chen, Wei;
Yang, Wanqi;
Lai, Yong

Publication type:

Article

Intravesical sequential gemcitabine/docetaxel for non-muscle invasive bladder cancer: tips and tricks for better efficacy and tolerability.

Published in:

2024

By:

Abou Chakra, Mohamad;
Moussa, Mohamad;
O'Donnell, Michael A.

Publication type:

Letter to the Editor

Chronic antibiotic suppressive therapy with dalbavancin: a case series.

Published in:

Journal of Chemotherapy (Taylor & Francis Ltd), 2024, v. 36, n. 8, p. 717, doi. 10.1080/1120009X.2024.2349442

By:

Pallotto, Carlo;
Tommasi, Andrea;
Albagini, Margherita;
Genga, Giovanni;
Svizzeretto, Elisabetta;
Gidari, Anna;
Tordi, Sara;
Francisci, Daniela

Publication type:

Article

Antihyperlipidemic drug rosuvastatin suppressed tumor progression and potentiated chemosensitivity by downregulating CCNA2 in lung adenocarcinoma.

Published in:

Journal of Chemotherapy (Taylor & Francis Ltd), 2024, v. 36, n. 8, p. 662, doi. 10.1080/1120009X.2024.2308975

By:

Tan, Xiang-Di;
Luo, Cui-Fang;
Liang, Si-Yu

Publication type:

Article

Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC).

Published in:

Journal of Chemotherapy (Taylor & Francis Ltd), 2024, v. 36, n. 8, p. 675, doi. 10.1080/1120009X.2024.2308978

By:

Landre, Thierry;
Chouaïd, Christos;
Sadaoui, Nassyma;
Bouharati, Djamila;
Taleb, Chérifa

Publication type:

Article

Blocking lncRNA HCG18 re-sensitizes Taxol resistant lung cancer cells to Taxol through modulating the miR-34a-5p/HDAC1 axis.

Published in:

Journal of Chemotherapy (Taylor & Francis Ltd), 2024, v. 36, n. 8, p. 682, doi. 10.1080/1120009X.2024.2308979

By:

Zhang, Fujun;
Wang, Juan;
Li, Haoyu;
Luo, Xiaoyu;
Xu, Qiuyue;
Liu, Lin;
Xu, Yunmin;
Yang, Kai;
Liu, Zijie;
Gong, Rong

Publication type:

Article

Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents.

Published in:

Journal of Chemotherapy (Taylor & Francis Ltd), 2024, v. 36, n. 8, p. 623, doi. 10.1080/1120009X.2023.2300217

By:

Manavi, Mohammad Amin;
Fathian Nasab, Mohammad Hosein;
Mohammad Jafari, Razieh;
Dehpour, Ahmad Reza

Publication type:

Article

Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study.

Published in:

Journal of Chemotherapy (Taylor & Francis Ltd), 2024, v. 36, n. 8, p. 654, doi. 10.1080/1120009X.2024.2305065

By:

Wei, Xiao-Chen;
Guo, Yuan-Yuan;
Zhang, Yi;
Bu, Yi-Shan;
Zhang, Feng-Ying

Publication type:

Article